Skip to content
10-Q

Quarterly Report

Janux Therapeutics, Inc. JANX

0000950170-25-067083

← back to feed
Filed
May 8, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 6, 2025 59.18M sh
Short Term Investments Q1 2025 · Mar 31, 2025 $940.4M
Short Term Investments Q1 2025 · Dec 31, 2024 $594.57M
Cash And Equivalents Q1 2025 · Mar 31, 2025 $73.74M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $430.61M
Current Liabilities Q1 2025 · Mar 31, 2025 $17.5M
Current Liabilities Q1 2025 · Dec 31, 2024 $17.46M
Total Liabilities Q1 2025 · Mar 31, 2025 $38.3M
Total Liabilities Q1 2025 · Dec 31, 2024 $38.74M
Current Assets Q1 2025 · Mar 31, 2025 $1.02B
Current Assets Q1 2025 · Dec 31, 2024 $1.03B
Total Assets Q1 2025 · Mar 31, 2025 $1.05B
Total Assets Q1 2025 · Dec 31, 2024 $1.06B
Shares Diluted Q1 2025 · Mar 31, 2024 49.05M sh
Capex Q1 2025 · Mar 31, 2024 $197K
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$14.84M
Stockholders Equity Q1 2025 · Mar 31, 2024 $655.76M
Stockholders Equity Q1 2025 · Dec 31, 2023 $344.35M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.30
Eps Basic Q1 2025 · Mar 31, 2024 −$0.30
Sga Expense Q1 2025 · Mar 31, 2024 $7.34M
Rd Expense Q1 2025 · Mar 31, 2024 $14.07M
Net Income Q1 2025 · Mar 31, 2024 −$14.76M
Operating Income Q1 2025 · Mar 31, 2024 −$20.16M
Revenue Q1 2025 · Mar 31, 2024 $1.25M